EA200501890A1 - Вирусы гриппа высокого титра для приготовления вакцин и генной терапии - Google Patents

Вирусы гриппа высокого титра для приготовления вакцин и генной терапии

Info

Publication number
EA200501890A1
EA200501890A1 EA200501890A EA200501890A EA200501890A1 EA 200501890 A1 EA200501890 A1 EA 200501890A1 EA 200501890 A EA200501890 A EA 200501890A EA 200501890 A EA200501890 A EA 200501890A EA 200501890 A1 EA200501890 A1 EA 200501890A1
Authority
EA
Eurasian Patent Office
Prior art keywords
high titer
gene therapy
flu viruses
preparing vaccines
viruses
Prior art date
Application number
EA200501890A
Other languages
English (en)
Other versions
EA012965B1 (ru
Inventor
Йошихиро Каваока
Original Assignee
Висконсин Эламни Рисёч Фаундэйшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Висконсин Эламни Рисёч Фаундэйшн filed Critical Висконсин Эламни Рисёч Фаундэйшн
Publication of EA200501890A1 publication Critical patent/EA200501890A1/ru
Publication of EA012965B1 publication Critical patent/EA012965B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к композициям, полезным для получения вирусов гриппа в высоких титрах, например, в отсутствие хелперных вирусов, содержащих последовательности генов из изолятов вирусов гриппа высоких титров.
EA200501890A 2003-05-28 2004-05-27 Композиция для получения реассортантного рекомбинантного вируса гриппа, способ получения указанного вируса и реассортантный рекомбинантный вирус гриппа EA012965B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47379803P 2003-05-28 2003-05-28
PCT/US2004/016680 WO2004112831A2 (en) 2003-05-28 2004-05-27 High titer recombinant influenza viruses for vaccines and gene therapy

Publications (2)

Publication Number Publication Date
EA200501890A1 true EA200501890A1 (ru) 2006-06-30
EA012965B1 EA012965B1 (ru) 2010-02-26

Family

ID=33539054

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501890A EA012965B1 (ru) 2003-05-28 2004-05-27 Композиция для получения реассортантного рекомбинантного вируса гриппа, способ получения указанного вируса и реассортантный рекомбинантный вирус гриппа

Country Status (19)

Country Link
US (1) US8475806B2 (ru)
EP (1) EP1631663B1 (ru)
JP (2) JP5215561B2 (ru)
KR (1) KR100908757B1 (ru)
CN (1) CN1826407B (ru)
AU (1) AU2004249133B2 (ru)
BR (1) BRPI0410702B1 (ru)
CA (1) CA2525953C (ru)
EA (1) EA012965B1 (ru)
ES (1) ES2593082T3 (ru)
HK (1) HK1082769A1 (ru)
HU (1) HUE030962T2 (ru)
IL (2) IL171831A (ru)
MX (1) MX342639B (ru)
NO (1) NO341506B1 (ru)
NZ (1) NZ543446A (ru)
UA (1) UA92132C2 (ru)
WO (1) WO2004112831A2 (ru)
ZA (1) ZA200510309B (ru)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
ES2217967B1 (es) * 2003-03-31 2006-01-01 Consejo Sup. Investig. Cientificas Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
JP5215561B2 (ja) 2003-05-28 2013-06-19 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン及び遺伝子治療のための高力価組換えインフルエンザ・ウイルス
ES2307345B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307346B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
CA2587510A1 (en) 2004-11-19 2007-04-19 Wisconsin Alumni Research Foundation Recombinant influenza vectors with tandem transcription units
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
EP1917361A4 (en) * 2005-06-21 2009-07-29 Medimmune Vaccines Inc METHODS AND COMPOSITIONS FOR EXPRESSING NEGATIVE SENSE RNA VIRUS IN CANINE CELLS
US7790434B2 (en) * 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
ES2310062B1 (es) * 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
ATE494906T1 (de) 2005-11-01 2011-01-15 Novartis Vaccines & Diagnostic Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
KR101484305B1 (ko) * 2006-03-10 2015-01-19 위스콘신 얼럼나이 리서어치 화운데이션 Ｈ3 말 인플루엔자 ａ 바이러스
JP2007259758A (ja) * 2006-03-28 2007-10-11 Wisconsin Alumni Research Foundation Ｈ３型ウマａ型インフルエンザウイルス
WO2007126810A2 (en) * 2006-03-31 2007-11-08 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
AU2013204811B2 (en) * 2006-04-19 2015-01-22 Medimmune, Llc Methods and compositions for expressing negative-sense viral rna in canine cells
DK2016194T3 (en) * 2006-04-19 2015-06-15 Medimmune Llc METHODS AND COMPOSITIONS FOR EXPRESSION OF VIRAL NEGATIVE SENSE RNA IN DOG CELLS
US20090017444A1 (en) * 2006-06-09 2009-01-15 Wisconsin Alumni Research Foundation Screening method for modulators of viral transcription or replication
EP2043681B1 (en) 2006-07-14 2015-10-07 Sanofi Pasteur Biologics, LLC Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins
KR20090096414A (ko) * 2006-09-29 2009-09-10 사노피 파스테르 바이오로직스 씨오 재조합 리노바이러스 벡터
WO2008128176A1 (en) * 2007-04-12 2008-10-23 Nucleonics, Inc. Influenza polynucleotides, expression constructs, compositions, and methods of use
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EP2493912B1 (en) * 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US20120015346A1 (en) * 2010-07-08 2012-01-19 New York Medical College Influenza virus detection and diagnosis
CA2875484C (en) * 2011-06-24 2019-11-05 Flugen, Inc. Influenza virus mutants and uses therefor
AU2013205478B9 (en) * 2012-03-02 2014-11-20 Seqirus UK Limited Influenza virus reassortment
JP2013099339A (ja) * 2013-01-04 2013-05-23 Wisconsin Alumni Research Foundation Ｈ３型ウマａ型インフルエンザウイルス
WO2015009743A1 (en) * 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
KR101493613B1 (ko) * 2013-10-25 2015-02-13 위스콘신 얼럼나이 리서어치 화운데이션 Ｈ3 말 인플루엔자 ａ 바이러스
EP3119883A4 (en) 2014-03-17 2018-01-10 Flugen, Inc. Influenza virus vectors and uses therefor
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
EP3307761A4 (en) 2015-06-09 2019-01-16 Sanofi Pasteur Inc. PROCESS FOR OPTIMIZING NUCLEOTIDE SEQUENCES COPING MANIPULATED INFLUENZA PROTEINS
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
JP6560056B2 (ja) * 2015-08-07 2019-08-14 ウィスコンシン アルムニ リサーチ ファンデイション Ｈ３型ウマａ型インフルエンザウイルス
RU2660562C2 (ru) * 2016-03-30 2018-07-06 Общество с ограниченной ответственностью "ФАРМИНТЕРПРАЙСЕЗ БИОТЕХ" Аттенуированный гриппозный вектор и мукозальная универсальная гриппозная вакцина на его основе
CN109477074B (zh) * 2016-02-19 2023-01-24 威斯康星旧生研究基金会 用于疫苗开发的改进的乙型流感病毒复制
JP2017038622A (ja) * 2016-11-21 2017-02-23 ウィスコンシン アルムニ リサーチ ファンデイション Ｈ３型ウマａ型インフルエンザウイルス
WO2020167432A2 (en) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4071618A (en) 1974-09-03 1978-01-31 Research Foundation For Microbial Diseases Of Osaka University Process for preparing virus disease live vaccines
JPS57136528A (en) 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
US5840520A (en) 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
EP0702085B2 (en) 1994-07-18 2010-01-13 Conzelmann, Karl-Klaus, Prof. Dr. Recombinant infectious non-segmented negative strand RNA virus
US5789229A (en) 1994-09-30 1998-08-04 Uab Research Foundation Stranded RNA virus particles
US5716821A (en) 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
ES2345643T3 (es) 1996-07-15 2010-09-28 The Government Of The Usa, As Represented By The Department Of Health And Human Services Produccion de vacunas a base de virus respiratorio sincitial atenuado, a partir de secuencias nucleotidicas clonadas.
EP0994949B1 (en) 1997-05-23 2011-03-09 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
KR100281676B1 (ko) * 1997-11-29 2001-04-02 신동권 신규한독감생백신바이러스
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
CN1350578B (zh) 1999-04-06 2010-05-12 威斯康星校友研究基金会 用于疫苗和基因治疗的重组流感病毒
AU5533601A (en) 2000-04-14 2001-10-30 Wisconsin Alumni Res Found Viruses comprising mutation ion channel protein
PT1317559E (pt) * 2000-04-28 2009-02-12 St Jude Childrens Res Hospital Sistema de transfecção de adn para a produção de vírus infecciosos de arn de cadeia negativa
EP1201760A1 (en) * 2000-10-30 2002-05-02 ARTEMIS Pharmaceuticals GmbH Influenza virus vector for human dendritic cells
CN103540614B (zh) 2002-02-13 2018-02-02 威斯康星旧生研究基金会 包装流感病毒载体的信号
AU2004232992A1 (en) 2003-04-23 2004-11-04 Wisconsin Alumni Research Foundation Recombinant influenza viruses holding a mutation in a transmembrane protein gene
WO2005028658A2 (en) 2003-05-28 2005-03-31 Wisconsin Alumni Research Foundation Recombinant influenza vectors with a polii promoter and ribozymes
JP5215561B2 (ja) 2003-05-28 2013-06-19 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン及び遺伝子治療のための高力価組換えインフルエンザ・ウイルス
CA2587510A1 (en) 2004-11-19 2007-04-19 Wisconsin Alumni Research Foundation Recombinant influenza vectors with tandem transcription units
WO2007126810A2 (en) * 2006-03-31 2007-11-08 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines

Also Published As

Publication number Publication date
JP5215561B2 (ja) 2013-06-19
CN1826407B (zh) 2013-09-11
JP2007518395A (ja) 2007-07-12
BRPI0410702B1 (pt) 2022-04-12
EP1631663A2 (en) 2006-03-08
WO2004112831A3 (en) 2005-03-24
IL238584B (en) 2020-06-30
NO20056074L (no) 2006-03-22
US20050003349A1 (en) 2005-01-06
AU2004249133A1 (en) 2004-12-29
JP2013059346A (ja) 2013-04-04
JP5695020B2 (ja) 2015-04-01
US8475806B2 (en) 2013-07-02
IL238584A0 (en) 2015-06-30
EA012965B1 (ru) 2010-02-26
AU2004249133B2 (en) 2009-05-28
ES2593082T3 (es) 2016-12-05
NZ543446A (en) 2008-06-30
KR100908757B1 (ko) 2009-07-22
CA2525953C (en) 2023-10-10
EP1631663B1 (en) 2016-08-24
CA2525953A1 (en) 2004-12-29
MX342639B (es) 2016-10-07
KR20060016095A (ko) 2006-02-21
CN1826407A (zh) 2006-08-30
HUE030962T2 (en) 2017-06-28
HK1082769A1 (zh) 2006-06-16
NO341506B1 (no) 2017-11-27
WO2004112831A2 (en) 2004-12-29
BRPI0410702A (pt) 2006-06-13
ZA200510309B (en) 2006-08-30
IL171831A (en) 2015-05-31
UA92132C2 (ru) 2010-10-11

Similar Documents

Publication Publication Date Title
EA200501890A1 (ru) Вирусы гриппа высокого титра для приготовления вакцин и генной терапии
EA201000076A1 (ru) Новые конструкты для экспрессии вируса гриппа
HK1207828A1 (en) Cell-derived viral vaccines with low levels of residual cell dna dna
ATE368729T1 (de) Rekombinante influenzaviren zur vakzinherstellung und gentherapie
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
MX346862B (es) Secuencias consenso de envoltura de vih y método para usar las mismas.
EA201201025A1 (ru) Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них
DE60139026D1 (de) Lebender influenza impfstoff und verfahren zu seiner herstellung
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
TW200732476A (en) Functional influenza virus like particles (VLPs)
MX2010008468A (es) Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante.
GB2386072A (en) Novel vaccine
EA201000277A1 (ru) Соединения для лечения гепатита с
EP1623015A4 (en) HA1 OF THE EQUINE-2 INFLUENZAVIRUS EXPRESSIVE DNA VACCINE
AU2002337083A1 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
HUP0303431A2 (hu) PRRS vírus élő legyengített törzsei
EA200601218A1 (ru) Респираторно-синцитиальный вирус с перекрёстно компенсированным геномным дефицитом
DE60040219D1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
ATE427119T1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
CY1116497T1 (el) Λειτουργικα ιομορφα σωματιδια γριπης (vlps)
CY1114693T1 (el) Στοχοθετημενη παροχη γονιδιων για εμβολιασμο δενδριτικων κυτταρων

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM